
SLS Valuation
Sellas Life Sciences Group Inc
- Overview
- Forecast
- Valuation
- Earnings
SLS Relative Valuation
SLS's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average, adjusted by weights. If the market price exceeds this fair value range, SLS is overvalued; if below, it's undervalued.
Historical Valuation
Sellas Life Sciences Group Inc (SLS) is now in the Fair zone, suggesting that its current forward PS ratio of 0.00 is considered Fairly compared with the five-year average of -3.36. The fair price of Sellas Life Sciences Group Inc (SLS) is between to according to relative valuation methord.
Relative Value
Fair Zone
-
Current Price:1.63
Fair
-5.56
PE
1Y
3Y
5Y
Trailing
Forward
0.00
EV/EBITDA
Sellas Life Sciences Group Inc. (SLS) has a current EV/EBITDA of 0.00. The 5-year average EV/EBITDA is -0.09. The thresholds are as follows: Strongly Undervalued below -0.93, Undervalued between -0.93 and -0.51, Fairly Valued between 0.33 and -0.51, Overvalued between 0.33 and 0.75, and Strongly Overvalued above 0.75. The current Forward EV/EBITDA of 0.00 falls within the Historic Trend Line -Fairly Valued range.
-4.38
EV/EBIT
Sellas Life Sciences Group Inc. (SLS) has a current EV/EBIT of -4.38. The 5-year average EV/EBIT is -3.02. The thresholds are as follows: Strongly Undervalued below -12.35, Undervalued between -12.35 and -7.69, Fairly Valued between 1.64 and -7.69, Overvalued between 1.64 and 6.30, and Strongly Overvalued above 6.30. The current Forward EV/EBIT of -4.38 falls within the Historic Trend Line -Fairly Valued range.
0.00
PS
Sellas Life Sciences Group Inc. (SLS) has a current PS of 0.00. The 5-year average PS is 10.57. The thresholds are as follows: Strongly Undervalued below -34.04, Undervalued between -34.04 and -11.74, Fairly Valued between 32.87 and -11.74, Overvalued between 32.87 and 55.17, and Strongly Overvalued above 55.17. The current Forward PS of 0.00 falls within the Historic Trend Line -Fairly Valued range.
0.00
P/OCF
Sellas Life Sciences Group Inc. (SLS) has a current P/OCF of 0.00. The 5-year average P/OCF is -1.36. The thresholds are as follows: Strongly Undervalued below -4.47, Undervalued between -4.47 and -2.92, Fairly Valued between 0.20 and -2.92, Overvalued between 0.20 and 1.76, and Strongly Overvalued above 1.76. The current Forward P/OCF of 0.00 falls within the Historic Trend Line -Fairly Valued range.
0.00
P/FCF
Sellas Life Sciences Group Inc. (SLS) has a current P/FCF of 0.00. The 5-year average P/FCF is -2.64. The thresholds are as follows: Strongly Undervalued below -9.30, Undervalued between -9.30 and -5.97, Fairly Valued between 0.69 and -5.97, Overvalued between 0.69 and 4.02, and Strongly Overvalued above 4.02. The current Forward P/FCF of 0.00 falls within the Historic Trend Line -Fairly Valued range.
Sellas Life Sciences Group Inc (SLS) has a current Price-to-Book (P/B) ratio of 6.26. Compared to its 3-year average P/B ratio of 6.38 , the current P/B ratio is approximately -1.88% higher. Relative to its 5-year average P/B ratio of 6.12, the current P/B ratio is about 2.18% higher. Sellas Life Sciences Group Inc (SLS) has a Forward Free Cash Flow (FCF) yield of approximately -19.21%. Compared to its 3-year average FCF yield of -53.26%, the current FCF yield is approximately -63.93% lower. Relative to its 5-year average FCF yield of -43.73% , the current FCF yield is about -56.07% lower.
6.26
P/B
Median3y
6.38
Median5y
6.12
-19.21
FCF Yield
Median3y
-53.26
Median5y
-43.73
Competitors Valuation Multiple
The average P/S ratio for SLS's competitors is 0.91, providing a benchmark for relative valuation. Sellas Life Sciences Group Inc Corp (SLS) exhibits a P/S ratio of 0.00, which is -100.00% above the industry average. Given its robust revenue growth of %, this premium appears unsustainable.
P/S
P/E
EV/EBITDA
EV/EBIT
P/S
Performance Decomposition
1Y
3Y
5Y
Market capitalization of SLS increased by 0.00% over the past 1 year. The primary factor behind the change was an decrease in Unknown from 0.00 to 0.00.
The secondary factor is the Unknown, contributed 0.00%to the performance.
Overall, the performance of SLS in the past 1 year is driven by Unknown.
People Also Watch

MRBK
Meridian Corp
14.840
USD
0.00%

MED
Medifast Inc
13.500
USD
+2.35%

PROP
Prairie Operating Co
2.695
USD
-2.00%

EML
Eastern Company
21.520
USD
0.00%

ABAT
American Battery Technology Co
2.618
USD
-5.49%

INSG
Inseego Corp
8.657
USD
+0.55%

MYFW
First Western Financial Inc
21.580
USD
0.00%

GNFT
Genfit SA
4.530
USD
+13.53%

UBFO
United Security Bancshares
8.800
USD
-1.57%
FAQ

Is Sellas Life Sciences Group Inc (SLS) currently overvalued or undervalued?
Sellas Life Sciences Group Inc (SLS) is now in the Fair zone, suggesting that its current forward PS ratio of 0.00 is considered Fairly compared with the five-year average of -3.36. The fair price of Sellas Life Sciences Group Inc (SLS) is between to according to relative valuation methord.

What is Sellas Life Sciences Group Inc (SLS) fair value?

How does SLS's valuation metrics compare to the industry average?

What is the current P/B ratio for Sellas Life Sciences Group Inc (SLS) as of Aug 18 2025?

What is the current FCF Yield for Sellas Life Sciences Group Inc (SLS) as of Aug 18 2025?

What is the current Forward P/E ratio for Sellas Life Sciences Group Inc (SLS) as of Aug 18 2025?
